Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997–2004)
Top Cited Papers
- 31 October 2009
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 10 (10), 957-966
- https://doi.org/10.1016/s1470-2045(09)70228-1
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- Treatment of Acute Lymphoblastic LeukemiaThe New England Journal of Medicine, 2006
- Therapy of low‐risk subsets of childhood acute lymphoblastic leukemia: When do we say enough?Pediatric Blood & Cancer, 2005
- Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trialBritish Journal of Haematology, 2005
- Causes of death – other than progressive leukemia – in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experienceLeukemia, 2005
- Childhood Leukemia — New Advances and ChallengesThe New England Journal of Medicine, 2004
- Dexamethasone‐associated toxicity during induction chemotherapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycinCancer, 2003
- Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer GroupBlood, 2003
- Pharmacokinetics of Vincristine Monotherapy in Childhood Acute Lymphoblastic LeukemiaPediatric Research, 2002
- Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemiaCancer, 2000
- High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group.Journal of Clinical Oncology, 1996